Furuhjelm 2009
ID: 6619ac895d70331b1cff9c62
6 Documentos
Cerrar
6 Referencias ( articles) loading Revertir Estudificar

Estudio primario

No clasificado

A randomised placebo controlled study of omega-3-fatty acid supplementation during pregnancy and lactation

Conferencia Allergy
Año 2007
Enlaces DOI
Cargando información sobre las referencias

Estudio primario

No clasificado

A randomised placebo controlled study of maternal n-3 fatty acid supplementation during pregnancy and lactation

Conferencia Allergy
Año 2008
Enlaces DOI
Cargando información sobre las referencias

Estudio primario

No clasificado

The effects of omega-3 fatty acid supplementation in pregnancy on maternal eicosanoid, cytokine, and chemokine secretion

Revista Pediatric research
Año 2009
Enlaces Pubmed DOI
Cargando información sobre las referencias
The incidence of allergic diseases has increased, and a relation between allergy and dietary fatty acids has been proposed. Modulation of the maternal immune function during pregnancy may have an impact on future clinical outcomes in the child. The aim of this study was to determine the effects of omega (ω)-3 long-chain polyunsaturated fatty acids (LCPUFA) supplementation during pregnancy on the plasma fatty acid composition in relation to the maternal immune function. Pregnant women with allergic disease in their immediate family were supplemented daily with 2.7 g ω-3 LCPUFA (n = 70) or 2.8 g soybean oil as placebo (n = 75) from the 25th gestational week. The proportions of eicosapentaenoic acid and docosahexaenoic acid in plasma/serum phospholipids increased in the ω-3-supplemented group, whereas arachidonic acid decreased during intervention. Lipopolysaccharide-induced prostaglandin E2 secretion from whole blood culture supernatants (n = 59) decreased in a majority of the ω-3-supplemented mothers (18 of 28, p = 0.002). The decreased prostaglandin E2 production was more pronounced among nonatopic than atopic mothers. The lipopolysaccharideinduced cytokine and chemokine secretion was not affected. Our results indicate that ω-3 LCPUFA supplementation during the last trimester may dampen certain immune responses involved in allergic inflammation. Copyright © 2009 International Pediatric Research Foundation, Inc.

Estudio primario

No clasificado

La suplementación con aceite de pescado durante el embarazo y la lactancia puede reducir el riesgo de alergia infantil.

automatic
Revista Acta paediatrica
Año 2009
Enlaces Pubmed DOI
Cargando información sobre las referencias
La ingesta materna de ácidos grasos omega-3 (ácidos grasos omega-3) los ácidos grasos poliinsaturados (PUFAs) durante el embarazo ha disminuido, posiblemente contribuyendo a un aumento de riesgo actual de la alergia infantil. Objetivo: Describir los efectos de la madre de omega-3 de cadena larga de suplementos de AGPI durante el embarazo y la lactancia sobre la incidencia de las enfermedades alérgicas en la infancia. Métodos: Ciento cuarenta y cinco mujeres embarazadas, afectados por la alergia a sí mismos o tener un esposo o hijo anterior con las alergias, se incluyeron en un ensayo clínico aleatorizado y controlado con placebo. La suplementación diaria materna con ácido eicosapentaenoico y 1,6 g 1,1 g de ácido docosahexaenoico, o el placebo se administró desde el 25 (t) semana de gestación en un promedio de 3-4 meses de la lactancia materna. Las pruebas cutáneas, la detección de circulación específicas de inmunoglobulina E (IgE) y los exámenes clínicos de los niños se llevaron a cabo. Resultados: La prevalencia de la alergia alimentaria periodo fue menor en el grupo omega-3 (1/52, 2%) en comparación con el grupo placebo (10/65, el 15%, p <0,05), así como la incidencia de la IgE asociada a eczema (grupo omega-3: 4/52, 8%; grupo placebo: 15/63, el 24%, p <0,05). Conclusión: la madre de omega-3 suplementos de ácidos grasos puede reducir el riesgo de alergia a los alimentos y eczema IgE asociado durante el primer año de vida en niños con antecedentes familiares de enfermedad alérgica.

Estudio primario

No clasificado

Th1 and Th2 chemokines, vaccine-induced immunity, and allergic disease in infants after maternal ω-3 fatty acid supplementation during pregnancy and lactation.

Revista Pediatric research
Año 2011
Enlaces Pubmed DOI
Cargando información sobre las referencias
We investigated whether the previously reported preventive effect of maternal ω-3 fatty acid supplementation on IgE-associated allergic disease in infancy may be mediated by facilitating a balanced circulating Th2/Th1 chemokine profile in the infant. Vaccine-induced immune responses at 2 y of age were also evaluated. Pregnant women, at risk of having an allergic infant, were randomized to daily supplementation with 1.6 g eicosapentaenoic acid and 1.1 g docosahexaenoic acid or placebo from the 25th gestational week through 3.5 mo of breastfeeding. Infant plasma was analyzed for chemokines (cord blood, 3, 12, 24 mo) and anti-tetanus and anti-diphtheria IgG (24 mo). High Th2-associated CC-chemokine ligand 17 (CCL17) levels were associated with infant allergic disease (p < 0.05). In infants without, but not with, maternal history of allergy, the ω-3 supplementation was related to lower CCL17/CXC-chemokine ligand 11 (CXCL11) (Th2/Th1) ratios (p < 0.05). Furthermore, in nonallergic, but not in allergic infants, ω-3 supplementation was linked with higher Th1-associated CXCL11 levels (p < 0.05), as well as increased IgG titers to diphtheria (p = 0.01) and tetanus (p = 0.05) toxins. Thus, the prospect of balancing the infant immune system toward a less Th2-dominated response, by maternal ω-3 fatty acid supplementation, seems to be influenced by allergic status.

Estudio primario

No clasificado

Allergic disease in infants up to 2 years of age in relation to plasma omega-3 fatty acids and maternal fish oil supplementation in pregnancy and lactation.

Revista Pediatric allergy and immunology
Año 2011
Enlaces Pubmed DOI
Cargando información sobre las referencias
We have previously reported a protective effect of maternal omega-3 long-chain polyunsaturated fatty acids (ω-3 LCPUFA) supplementation in pregnancy and lactation on IgE-associated eczema and food allergy in the infant during the first year of life. Here we investigate whether the effects of the LCPUFA supplementation on IgE-associated diseases last up to 2 yr of age and assess the relationship between plasma proportions of ω-3 PUFAs and the frequency and severity of infant allergic disease. 145 pregnant women, at risk of having an allergic infant, were randomized to daily supplementation with 1.6 g eicosapentaenoic acid (EPA) and 1.1 g docosahexaenoic acid (DHA) or placebo starting in the 25th gestational week and continuing through 3.5 months of breastfeeding. Clinical examinations, skin prick tests and analysis of maternal and infant plasma phospholipid fatty acids and infant specific IgE were performed. No difference in the prevalence of allergic symptoms was found between the intervention groups. The cumulative incidence of IgE-associated disease was lower in the ω-3-supplemented group (6/54, 13%) compared with the placebo group (19/62, 30%, p=0.01). Higher maternal and infant proportions of DHA and EPA were associated with lower prevalence of IgE associated disease (p=0.01-0.05) in a dose-dependent manner. Higher maternal and infant proportions of DHA and EPA were found if the infants presented none, when compared with multiple allergic symptoms, (p<0.05) regardless of sensitization. In summary, the ω-3 supplementation offered no obvious preventive effect on the prevalence of clinical symptoms of allergic disease, but the decrease in cumulative incidence of IgE-associated disease seen during the first year still remained until 2 yr of age. Furthermore, high proportions of DHA and EPA in maternal and infant plasma phospholipids were associated with less IgE-associated disease and a reduced severity of the allergic phenotype.